Last reviewed · How we verify
NCT06251037: YAM
"Youth Aware of Mental Health" in Galicia
NA trial testing Youth Aware of Mental Health in Galicia in Suicide Awareness in 4,453 participants. Status unknown.
15 June 2024
Quick facts
| Lead sponsor | Fundacin Biomedica Galicia Sur |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 4,453 |
| Start date | 2 February 2024 |
| Primary completion | 15 June 2024 |
| Estimated completion | 15 June 2025 |
| Sites | 68 locations across Spain |
Drugs / interventions tested
- Youth Aware of Mental Health in Galicia
Conditions studied
- Suicide Awareness — all drugs for Suicide Awareness →
- Suicidal Ideation — all drugs for Suicidal Ideation →
- Suicide, Attempted — all drugs for Suicide, Attempted →
- Depressive Symptoms — all drugs for Depressive Symptoms →
Sponsor
Fundacin Biomedica Galicia Sur — full company profile →
Who can join
Adults 13 to 16, any sex, with Suicide Awareness or Suicidal Ideation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this interventional study is to assess the effectiveness of the universal suicide prevention program "Youth Aware of Mental Health" in 3rd-year secondary education students in Galicia. The main questions it aims to answer are: * Is the YAM program effective in reducing severe suicidal ideation at 12 months from baseline within the experimental group and compared to the control group? * Is the YAM program effective in preventing the incidence of new suicidal attempts, 12 months from baseline in the experimental group compared to the control group? All participants in this study will be asked to: Complete a survey at baseline and after 12 months, consisting of measures for suicidal ideation and behavior, depressive symptoms, seeking help behaviors, bullying, problematic internet use, and emotional distress. Only those allocated to the experimental group will be asked to: Undergo the YAM program, an evidence-based intervention structured into five one-hour class group sessions (45-50 min.), focused on problem-solving by peers. The program consists of interactive presentations, dilemma discussions, role-playing, and reflection, all moderated by a trained YAM instructor. Twelve months after the intervention, all participants will undergo a re-evaluation using the same protocol. The researchers will compare differences in pre- and post-measures within the experimental and control groups, as well as between both groups, to assess the impact of the YAM intervention on outcomes such as suicidal ideation and attempts. At the end of the study, those who were allocated to the control group are going to be offered the YAM intervention program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06251037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fundacin Biomedica Galicia Sur trials
Trials by the same sponsor.
- NCT07310953 — Clinical Utility of the Numerical Verbal Scale (NVS) and the Pain and Functional Activity Scale (PFAS) in the Management · NA · recruiting
- NCT07376616 — Cardiovascular Research in EMbarazo and MAternity (EMMA). Study on Heart Rate Variability and Hemodynamic Adaptations Du · recruiting
- NCT06987903 — Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Su · NA · recruiting
- NCT07275385 — Advanced Cutaneous Evaluator (ACE): Estimation of Clinical and Economic Impact · NA · completed
- NCT05513261 — Clinical Validation of PolyDeep: an Artificial Intelligence-based Computer-aided Polyp Detection (CADe) and Characteriza · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06251037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacin Biomedica Galicia Sur
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06251037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing